Maropitant

Print/View PDF

Sign in to continue reading this article

Not registered? Create an account for free to read full articles on www.veterinaryteambrief.com.

To access full articles on www.veterinaryteambrief.com, please sign in below.

Busy? Sign in Faster. Sign into www.veterinaryteambrief.com with your social media account.
Neurokinin-1 Receptor Antagonist, Antiemetic (Systemic Drug)

Prescriber Highlights

  • Veterinary-approved antiemetic for dogs 8 weeks of age or older and cats 16 weeks of age or older
  • Acts at the emetic center and is effective for antiemesis both peripherally and centrally
  • Subcutaneous injection is FDA-approved for prevention and treatment of acute vomiting in dogs and treatment of vomiting in cats
  • The oral dose is higher than the subcutaneous dose because of decreased oral bioavailability 
  • Refrigerating the injectable solution may reduce pain at the injection site
Uses, Indications
  • The injectable solution is indicated for dogs 8 weeks of age or older for prevention and treatment of acute vomiting
  • Oral tablets are indicated for prevention of acute vomiting and motion sickness with vomiting in dogs
  • The injectable solution is approved for treatment of vomiting in cats 16 weeks of age or older
Contraindications, Precautions, Warnings
  • Contraindications

If vomiting persists despite treatment, further evaluation for an underlying cause is warranted

  • Precautions 

Use with caution in patients with hepatic disease because maropitant is hepatically metabolized

  • Warnings

Use with caution in puppies less than 11 weeks of age; higher frequency and greater severity of histologic evidence of bone marrow hypoplasia has been observed in puppies treated with maropitant

Side Effects
  • Well tolerated in most patients 
  • Swelling and pain at the injection site have been reported in dogs following SQ administration
  • Pretravel vomiting and hypersalivation are the most common side effects seen after oral administration at the dose motion sickness prevention requires
Drug Interactions
  • Biotransformed in the liver by CYP450 enzymes and highly protein bound and therefore susceptible to various drug interactions (eg, chloramphenicol, phenobarbital, erythromycin, ketoconazole, itraconazole, NSAIDs); however, specific drug interactions have yet to be investigated
Monitoring
  • Clinical efficacy is measured by decreased frequency of vomiting and side effects
Client Information
  • Vomiting may occur after administration, so giving the medication with a small meal may help
  • If splitting tablets, wrap remaining portions tightly in foil until they are used
Dosage Forms
  • Maropitant citrate injectable solution: 10 mg/mL
  • Maropitant citrate oral tablets: 16 mg, 24 mg, 60 mg, 160 mg

Compiled and summarized from Plumb’s Veterinary Drugs by Shannon Palermo, VMD

Information about this drug was adapted from Plumb’s Veterinary Drugs. Further details and more therapeutics can be found with a subscription at plumbsveterinarydrugs.com

Material from Veterinary Team Brief may not be reproduced, distributed, or used in whole or in part without prior permission of Educational Concepts, LLC. For questions or inquiries please contact us.

Veterinary Team Brief delivers practical skills for team-based medicine—with clinical strategies for team training, peer-reviewed credibility, concise content, essential training modules, and easy-to-implement protocols. From the publisher of Clinician's Brief.